Back to List
Sumatriptan and Naproxen Sodium for the
Acute Treatment of Migraine
Smith TR, Sunshine A, Stark, SR, et al.
Posted: October 2005
Objective: To evaluate the efficacy and
tolerability of treatment with a combination of sumatriptan
50 mg.(encapsulated) and naproxen sodium 500 mg. administered
concurrently in the acute treatment of migraine.
Background: The pathogenesis of migraine involves
multiple peripheral and central neural mechanisms that individually
have been successful targets for acute (abortive) and preventive
treatment. This suggests that multi-mechanism therapy, which acts
on multiple target sites, may confer improved efficacy and symptom
relief for patients with migraine.
Conclusions: This is among the first prospective
studies to demonstrate that multi-mechanism acute therapy for
migraine, combining a triptan and an analgesic, is well tolerated
and offers improved clinical benefits over monotherapy with these
selected standard antimigraine treatments. Specifically,
sumatriptan 50 mg. (encapsulated) and naproxen sodium 500 mg.
resulted in significantly superior pain relief as compared to
monotherapy with either sumatriptan 50 mg. or naproxen sodium
500 mg. for the acute treatment of migraine. Because encapsulation
of the sumatriptan for blinding purposes may have altered its
pharmacokinetic profile and thereby decreased the efficacy
responses, additional studies are warranted that do not involve
encapsulaton of the active treatments and assess the true onset of
action of multi-mechanism therapy in migraine. This study did show
that the combination of sumatriptan and naproxen sodium was well
tolerated and that there was no significant increase in the
incidence of adverse events compared to monotherapy.